Logo
  • Search
  • Subscribe
  • Login
  • News
  • Business
  • Opinion
  • Archive
  • Jobs Market
  • About DT
  • Contact
  • Search
  • Subscribe
  • Login

GAVI funds big pharma while Indian drug firm could produce for less

News June 23, 2011

Donors recently committed USD 4.3 billion in new support to GAVI; one-third of this will finance the purchase of pneumococcal vaccine. Critics say that GAVI is paying too much for pneumo vaccine, while Bill Gates “feels great” about the prices GAVI has achieved.

In an interview with Development Today, the head of the Indian drug firm Serum Institute says he will have a pneumonia vaccine on the market by 2015 at a fraction of what GAVI is currently paying Western pharmaceutical companies. Had he received donor support three years ago, he would have been able to produce a cheaper vaccine by 2012-13.

jadhav_suresh_page_3.jpg

Suresh Jadhav is Executive Director of Serum Institute.

If you are new to Development Today and would like to continue reading this article, send us a mail at subscribers@devtoday.no, including your name, title, organisation, and email contact, and you will receive a free Guest Pass, along with weekly updates.

Log in or subscribe

  • Home
  • Archive
  • 2011
  • DT 8 / 2011
  • GAVI funds big pharma while Indian drug firm could produce for less

Development Today AS
Box 140
1371 Asker
Norway
Tel: +47 66902660
E-mail: devtoday@devtoday.no

  • News
  • Business
  • Opinion
  • Archive
  • About DT
  • Privacy and Cookie policy
  • Contact
  • Log in
  • Subscribe

Design and development: Snapper Net Solutions